Literature DB >> 32759621

Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial.

Neeraj Narula1, Emily C L Wong1, Achuthan Aruljothy1, Parambir S Dulai2, Jean-Frederic Colombel3, John K Marshall1, Marc Ferrante4, Walter Reinisch5.   

Abstract

INTRODUCTION: It is unclear how baseline endoscopic characteristics in Crohn's disease (CD) affect the ability to achieve endoscopic remission (ER). We aimed to determine the endoscopic prognostic factors that influence achieving ER in CD.
DESIGN: This post hoc analysis of SONIC (NCT00094458; YODA #2019-3980) evaluated baseline and week 26 endoscopy indices in 172 patients using the CD Endoscopic Index of Severity (CDEIS) and the Simple Endoscopic Score for CD. The impact of baseline ulcer depth and size on achieving week 26 ER was assessed using multivariate logistic regression models adjusted for confounders.
RESULTS: The ER rate of ileal ulcers was significantly lower than ER rates throughout the colon (P < 0.0001). Ileal ulcers >2 cm were less likely to achieve ER compared with smaller ulcers {odds ratio (OR) 0.31 (95% confidence interval [CI] 0.11-0.89), P = 0.03}. Similarly, rectal ulcers >2 cm were associated with reduced odds of week 26 ER (OR 0.26 [95% CI 0.08-0.80], P = 0.02). Ulcer size in other colonic segments did not affect the achievement of week 26 ER. Deep ileal and rectal ulcers >2 cm compared with smaller or superficial ulcers were even less likely to achieve week 26 ER (ileum: OR 0.10, 95% CI 0.02-0.68, P = 0.02; rectum: OR 0.12, 0.02-0.82, P = 0.03). High baseline Simple Endoscopic Score for CD (≥16) or CDEIS scores (≥12) did not affect achieving week 26 ER. DISCUSSION: Patients with larger and deep ulcers in the ileum or rectum may have difficulty achieving ER. Overall degree of endoscopic inflammation as measured numerically by endoscopic scores does not affect the likelihood of achieving week 26 ER.

Entities:  

Mesh:

Year:  2020        PMID: 32759621     DOI: 10.14309/ajg.0000000000000617

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  4 in total

1.  Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn's Disease.

Authors:  Neeraj Narula; Emily C L Wong; Jean-Frederic Colombel; William J Sandborn; Marc Ferrante; John K Marshall; Walter Reinisch; Parambir S Dulai
Journal:  J Crohns Colitis       Date:  2022-05-10       Impact factor: 10.020

2.  Efficacy of infliximab treatment on the mucosal healing of different intestinal segments in patients with ileocolonic Crohn's disease.

Authors:  Yaling Wu; Lei Zhang; Jingli Cao; Haichao Wang; Chen Ye; Deji Zhuoma; Pengyu Yang; Xiaolei Wang
Journal:  Therap Adv Gastroenterol       Date:  2020-12-21       Impact factor: 4.409

Review 3.  Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises.

Authors:  Dahham Alsoud; Séverine Vermeire; Bram Verstockt
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-01-26

Review 4.  Ileal and colonic Crohn's disease: Does location makes a difference in therapy efficacy?

Authors:  Raja Atreya; Christian Bojarski; Anja A Kühl; Zlatko Trajanoski; Markus F Neurath; Britta Siegmund
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-03-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.